ClinicalTrials.gg

Program

ICP-488

A development code. Also written as “ICP-488 Tablets”.

Its studies are mostly in Psoriasis · Lupus Erythematosus, Cutaneous, led by InnoCare Pharma.

Furthest: phase 3, since Feb 18, 20255 company-led studies, 3 open or runningNext primary completion: Mar 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
InnoCare Pharma53 open or runningphase 3since Feb 18, 2025Jun 24, 2022Mar 2027phase 2 · NCT07440537

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 24, 2022First study: phase 1 study in PsoriasisFirst studyNCT05451199 · 154 enrolled · China
  2. Oct 26, 2023Phase 2 study in Moderate to Severe Plaque PsoriasisNCT06109818 · 129 enrolled · China
  3. Feb 18, 2025Phase 3 study in Plaque Psoriasis PatientsNCT06842199 · 383 planned · China
  4. Feb 10, 2026Phase 2 study in Lupus Erythematosus, CutaneousNCT07440537 · 105 planned · China
  5. Jul 21, 2026Phase 2 study in Primary Sjögren's SyndromeNCT07727486 · 240 planned · China

Ahead

  1. Mar 2027Primary completion: phase 2 study in Lupus Erythematosus, CutaneousNCT07440537
  2. Dec 2028Primary completion: phase 2 study in Primary Sjögren's SyndromeNCT07727486

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07727486Primary Sjögren's Syndrome · China2Not yet recruitingDec 2028240
NCT07440537Lupus Erythematosus, Cutaneous · China2RecruitingMar 2027105
NCT06842199Plaque Psoriasis Patients · China3RecruitingMay 2026383
NCT06109818Moderate to Severe Plaque Psoriasis · China2CompletedAug 5, 2024129
NCT05451199Psoriasis · China1UNKNOWNOct 30, 2023154

How it is read

Names in the registry

  • “ICP-488 Tablets”, 5 entries
  • “ICP-488”, 1 entry

Codes read as this program: ICP488.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.